Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion - Reuters
Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value."
— Marc Casper , Executive
Key People
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY0NwSmdCN3JITGNZUllySnRDZWtjRUhreGN1MXg3aDZTV19RRDBTY0hKaFd3QS02UkdJdUpqaFNLM2FyN1VhdjNldGxMRTdVT04tU1NFeWRMSEwtVWRtR0x2NmFWc0NWWGg5VElXWHpvcDU2RGdRRTZUYkktcEt1M0p3SEFwNWhrQThDaHB1SUhoSUNkZ1JIajcyN3NtOG9rNmZUdlZDcnpFQUIxZDR1NC1jVVhTbzNMRkYxc1lIOWF5eWM?oc=5" target="_blank">Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion</a> <font color="#6f6f6f">Reuters</font>
Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for approximately $1.08 billion, comprising cash and a $50 million seller note. The microbiology unit, part of Thermo Fisher's specialty diagnostics segment, generated $645 million in revenue in 2025. The transaction is expected to close in the second half of 2026 and may dilute adjusted earnings per share by $0.15 in the first full year after closing.
Thermo Fisher Scientific announced the sale of its microbiology business to private equity firm Astorg for $1.08 billion. The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical, and food safety applications. The unit recorded $645 million in revenue in 2025. The transaction is expected to close in the second half of 2026 and may dilute adjusted earnings per share by $0.15 in the first full year after closing.
Thermo Fisher Scientific announced it will sell its microbiology business to private equity firm Astorg for about $1.08 billion. The deal includes cash and a $50 million seller note. The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical, and food safety applications. The unit, part of Thermo Fisher's specialty diagnostics segment, recorded $645 million in revenue in 2025. The company expects the transaction to close in the second half of 2026 and anticipates a dilution of $0.15 to adjusted earnings per share in the first full year after closing.
Similar Stories
Related coverage based on topic and tags
Four signs it is about to get uglier in the bond market as yields rise - Reuters
Four signs it is about to get uglier in the bond market as yields rise Reuters
October 9, 2026 at 04:18 PMAfrica's biggest IPO exposes continent's cross-border investing barriers - Reuters
Africa's biggest IPO exposes continent's cross-border investing barriers Reuters
October 9, 2026 at 05:03 AMCOMMENTARY: Five charts sounding the alarm for stretched US markets - Reuters
COMMENTARY: Five charts sounding the alarm for stretched US markets Reuters
October 8, 2026 at 03:18 PMMorning Bid: Sovereign bonds shouldered aside as AI takes their turf - Reuters
Morning Bid: Sovereign bonds shouldered aside as AI takes their turf Reuters
October 8, 2026 at 04:31 AM'Stop throwing shade' - the woman trying to stop firms leaving the UK
British people need more incentives to invest in big firms listed in the UK, Dame Julia Hoggett, boss of the London Stock Exchange, says.
October 7, 2026 at 11:00 PMMcKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal - Reuters
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal Reuters
October 6, 2026 at 04:30 PM